Corcept Cash vs Non Current Assets Total Analysis

CORT Stock  USD 52.17  1.27  2.50%   
Corcept Therapeutics financial indicator trend analysis is way more than just evaluating Corcept Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corcept Therapeutics is a good investment. Please check the relationship between Corcept Therapeutics Cash and its Non Current Assets Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Cash vs Non Current Assets Total

JavaScript chart by amCharts 3.21.1520142016201820202022202425M50M100M150M200M250M300M350M400M 5M10M20M30M40M50M60M70M80M90M100M110M120M130M140M150M160M170M
JavaScript chart by amCharts 3.21.15Cashtotal: 2.3BNon Current Assets Totaltotal: 734.4M

Cash vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corcept Therapeutics Cash account and Non Current Assets Total. At this time, the significance of the direction appears to have weak relationship.
CashNon Current Assets TotalDiversified AwayCashNon Current Assets TotalDiversified Away100%
The correlation between Corcept Therapeutics' Cash and Non Current Assets Total is 0.31. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Corcept Therapeutics Incorporated, assuming nothing else is changed. The correlation between historical values of Corcept Therapeutics' Cash and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Corcept Therapeutics Incorporated are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Cash i.e., Corcept Therapeutics' Cash and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

0.31
Relationship DirectionPositive 
Relationship StrengthVery Weak

Cash

Cash refers to the most liquid asset of Corcept Therapeutics, which is listed under current asset account on Corcept Therapeutics Incorporated balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Corcept Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Corcept Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.
Most indicators from Corcept Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Selling General Administrative is likely to gain to about 193.1 M in 2024. Tax Provision is likely to gain to about 19.3 M in 2024
 2021 2022 2023 2024 (projected)
Other Operating Expenses241.5M289.2M375.1M393.8M
Research Development113.9M131.0M184.4M193.6M

Corcept Therapeutics fundamental ratios Correlations

0.760.750.930.740.820.820.50.981.00.850.4-0.160.93-0.730.51-0.760.90.860.960.970.520.030.460.990.86
0.760.890.820.30.90.840.340.770.730.790.21-0.470.58-0.590.08-0.330.830.880.760.640.38-0.25-0.050.690.8
0.750.890.870.190.930.910.320.810.70.750.17-0.360.6-0.490.11-0.220.750.910.690.60.36-0.370.00.660.81
0.930.820.870.480.870.890.430.940.910.890.33-0.230.79-0.640.3-0.510.870.970.830.830.47-0.080.240.870.89
0.740.30.190.480.370.310.550.640.780.520.530.230.87-0.560.74-1.00.540.310.770.860.520.230.730.820.44
0.820.90.930.870.370.910.30.870.780.730.12-0.490.7-0.530.09-0.40.880.860.810.720.33-0.150.00.760.78
0.820.840.910.890.310.910.430.880.760.680.27-0.320.64-0.410.13-0.340.80.880.830.720.480.00.050.760.77
0.50.340.320.430.550.30.430.440.480.330.970.540.47-0.10.36-0.530.180.330.560.510.990.160.330.510.38
0.980.770.810.940.640.870.880.440.970.830.31-0.240.9-0.680.44-0.670.920.880.940.940.470.010.390.960.86
1.00.730.70.910.780.780.760.480.970.860.39-0.150.95-0.760.56-0.80.90.820.940.980.50.020.510.990.85
0.850.790.750.890.520.730.680.330.830.860.29-0.180.77-0.830.39-0.550.790.910.740.760.36-0.350.30.790.86
0.40.210.170.330.530.120.270.970.310.390.290.690.39-0.080.4-0.50.030.240.440.420.940.130.370.410.31
-0.16-0.47-0.36-0.230.23-0.49-0.320.54-0.24-0.15-0.180.69-0.010.30.42-0.19-0.57-0.32-0.17-0.080.490.060.46-0.12-0.26
0.930.580.60.790.870.70.640.470.90.950.770.39-0.01-0.70.69-0.890.790.680.90.970.470.010.650.960.71
-0.73-0.59-0.49-0.64-0.56-0.53-0.41-0.1-0.68-0.76-0.83-0.080.3-0.7-0.410.59-0.75-0.66-0.63-0.69-0.120.39-0.36-0.71-0.81
0.510.080.110.30.740.090.130.360.440.560.390.40.420.69-0.41-0.730.260.20.470.610.33-0.030.980.580.29
-0.76-0.33-0.22-0.51-1.0-0.4-0.34-0.53-0.67-0.8-0.55-0.5-0.19-0.890.59-0.73-0.58-0.35-0.79-0.88-0.49-0.22-0.72-0.84-0.47
0.90.830.750.870.540.880.80.180.920.90.790.03-0.570.79-0.750.26-0.580.830.870.850.220.010.20.880.83
0.860.880.910.970.310.860.880.330.880.820.910.24-0.320.68-0.660.2-0.350.830.750.720.39-0.260.120.770.9
0.960.760.690.830.770.810.830.560.940.940.740.44-0.170.9-0.630.47-0.790.870.750.960.570.150.410.960.78
0.970.640.60.830.860.720.720.510.940.980.760.42-0.080.97-0.690.61-0.880.850.720.960.520.140.581.00.77
0.520.380.360.470.520.330.480.990.470.50.360.940.490.47-0.120.33-0.490.220.390.570.520.150.310.530.42
0.03-0.25-0.37-0.080.23-0.150.00.160.010.02-0.350.130.060.010.39-0.03-0.220.01-0.260.150.140.150.060.1-0.28
0.46-0.050.00.240.730.00.050.330.390.510.30.370.460.65-0.360.98-0.720.20.120.410.580.310.060.530.21
0.990.690.660.870.820.760.760.510.960.990.790.41-0.120.96-0.710.58-0.840.880.770.961.00.530.10.530.81
0.860.80.810.890.440.780.770.380.860.850.860.31-0.260.71-0.810.29-0.470.830.90.780.770.42-0.280.210.81
Click cells to compare fundamentals

Corcept Therapeutics Account Relationship Matchups

Corcept Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets412.3M571.7M423.8M583.4M621.5M652.6M
Other Current Liab30.1M(11.5M)39.1M58.1M65.4M68.7M
Total Current Liabilities41.1M10.6M6.9M81.6M104.5M109.7M
Accounts Payable7.5M10.6M6.9M12.0M17.4M18.3M
Cash315.3M476.9M335.8M436.6M135.6M116.6M
Other Current Assets6.0M6.7M10.3M45.0M41.6M43.6M
Total Liab41.1M48.4M48.0M81.6M114.8M120.6M
Common Stock120K122K127K131K133K85.9K
Property Plant Equipment1.1M1.7M1.0M1.8M2.0M2.1M
Total Stockholder Equity371.2M523.3M375.8M501.8M506.7M532.0M
Other Assets61.1M52.9M43.5M77.5M89.1M93.5M
Common Stock Shares Outstanding122.6M124.2M126.0M116.0M111.7M83.1M
Liabilities And Stockholders Equity412.3M571.7M423.8M583.4M621.5M652.6M
Other Stockholder Equity394.4M440.3M180.9M206.2M103.4M98.3M
Short Term Investments244.7M364.5M145.9M365.3M232.7M244.3M
Property Plant And Equipment Net3.4M2.5M514K1.1M315K559.2K
Net Debt(311.9M)(474.3M)(335.3M)(435.5M)(135.4M)(142.2M)
Retained Earnings(23.6M)82.5M195.0M296.4M402.5M422.7M
Non Current Assets Total59.7M47.5M42.4M84.7M162.9M171.0M
Non Currrent Assets Other10.5M13.4M14.4M17.2M14.8M15.5M
Cash And Short Term Investments315.3M476.9M335.8M436.6M368.2M386.6M
Common Stock Total Equity117K120K122K127K146.1K87.7K
Non Current Liabilities Total1.9M37.8M41.0M9.1M10.3M12.7M
Property Plant And Equipment Gross4.5M4.2M514K1.1M315K299.3K
Total Current Assets352.6M524.2M381.4M498.7M458.6M481.6M
Accumulated Other Comprehensive Income261K415K(227K)(869K)609K639.5K
Net Tangible Assets371.2M523.3M375.8M501.8M577.1M606.0M
Retained Earnings Total Equity(117.7M)(23.6M)82.5M195.0M224.2M235.4M
Capital Surpluse417.2M457.1M516.1M591.3M680.1M426.4M
Inventory17.4M21.2M18.0M17.0M7.7M9.6M
Net Receivables19.9M26.2M27.6M31.1M41.1M43.2M
Net Invested Capital371.2M523.3M375.8M501.8M506.7M431.5M
Long Term Investments39.4M36.2M112.3M4.9M57.2M41.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.